RCVS: The Rational Approach to Diagnosis and Treatment
Status:
Withdrawn
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized clinical trial of short-acting nimodipine versus twice daily extended
release verapamil to treat patients presenting with Reversible Cerebral Vasoconstriction
Syndrome (RCVS).